Rova-T

Rova-T (rovalpituzumab tesirine) is an investigational antibody drug conjugate targeting the cancer stem cell-associated target delta-like protein 3 (DLL3). It is also being investigated as a combination therapy with Bristol-Myers Squibb’s Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a second-line treatment for extensive-stage small cell lung cancer (SCLC).

Type of Molecule

Biologic

Target

DLL3

Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted, Approved)
Small Cell Lung Cancer (3L SCLC) n/a
Phase 2
Small Cell Lung Cancer (2L SCLC) n/a
Phase 3
Small Cell Lung Cancer (1L SCLC) n/a
Phase 3
Neuroendocrine Tumors n/a
Phase 1